These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 26099069

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
    Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H.
    Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.
    Benhamú B, Martín-Fontecha M, Vázquez-Villa H, Pardo L, López-Rodríguez ML.
    J Med Chem; 2014 Sep 11; 57(17):7160-81. PubMed ID: 24850589
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. N-Skatyltryptamines-Dual 5-HT6R/D2R Ligands with Antipsychotic and Procognitive Potential.
    Hogendorf A, Hogendorf AS, Kurczab R, Satała G, Szewczyk B, Cieślik P, Latacz G, Handzlik J, Lenda T, Kaczorowska K, Staroń J, Bugno R, Duszyńska B, Bojarski AJ.
    Molecules; 2021 Jul 29; 26(15):. PubMed ID: 34361754
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.
    Wicke K, Haupt A, Bespalov A.
    Expert Opin Investig Drugs; 2015 Jul 29; 24(12):1515-28. PubMed ID: 26548316
    [Abstract] [Full Text] [Related]

  • 13. Targeting 5-HT receptors for the treatment of obesity.
    Sargent BJ, Henderson AJ.
    Curr Opin Pharmacol; 2011 Feb 29; 11(1):52-8. PubMed ID: 21330209
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.
    Holenz J, Mercè R, Díaz JL, Guitart X, Codony X, Dordal A, Romero G, Torrens A, Mas J, Andaluz B, Hernández S, Monroy X, Sánchez E, Hernández E, Pérez R, Cubí R, Sanfeliu O, Buschmann H.
    J Med Chem; 2005 Mar 24; 48(6):1781-95. PubMed ID: 15771424
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Structure-activity relationships of serotonin 5-HT7 receptors ligands: A review.
    Thirumaran SL, Lepailleur A, Rochais C.
    Eur J Med Chem; 2019 Dec 01; 183():111705. PubMed ID: 31581003
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Serotonin receptors of type 6 (5-HT6): what can we expect from them?
    Marazziti D, Baroni S, Catena Dell'Osso M, Bordi F, Borsini F.
    Curr Med Chem; 2011 Dec 01; 18(18):2783-90. PubMed ID: 21649582
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.